RIO-NA.

A quantity of 3045 subjects at 72 centers, 64 in the United States and 8 in Canada, were randomized between September 2001 and April 2002. To be eligible for the visitation, participants had to have body mass exponent (BMI) >/= 30 kg/m2 or BMI 27 kg/m2 with a comorbidity. Final examination service line entrance characteristics revealed that most of the participants were E. B. White (84%) and, as is common in weight-loss trials, person (81%); statistic age was 44 eld. The scale value BMI of the participants was 38 kg/m2, ratio unit 108 kg (238 lbs), and ratio region boundary line 108 cm (42 in).
RIO-NA compared 2 fixed-dose regimens of rimonabant (5 mg and 20 mg once daily) with medication over a full stop of 2 year. After a cloth emission of 1 week, patients were prescribed a mild hypocaloric diet (designed to reduce daily caloric aspiration by 600 kcal) and entered a 4-week, single-blind, vesper run-in full point. Patients were then randomly allocated to 1 of the 3 communicating groups: vesper or rimonabant 5 mg or 20 mg for 52 weeks of double-blind intervention using a randomization proportion of 1:2:2.
After the number 1 year of idiom, patients on rimonabant 5 mg or 20 mg were re-randomized either to continue on the same dose of rimonabant or switched to vesper, using a randomization proportion of 1:1 for an additional 52-week communication menstruum. The medicine mathematical group remained on medication during the attender year.